Taipei Heart Institute (THI), Taipei Medical University

Medicine & Life Sciences

1. Atrial Fibrillation 100%
2. Pulmonary Veins 84%
3. Cardiac Myocytes 61%
4. Taiwan 45%
5. Heart Failure 44%
6. Calcium 40%
7. Endothelial Cells 33%
8. Endothelin-1 31%
9. Cardiac Arrhythmias 31%
10. Catheter Ablation 31%
11. Coronary Vessels 30%
12. Heart Atria 28%
13. Blood Pressure 27%
14. trilinolein 26%
15. Myocardial Infarction 25%
16. Cohort Studies 25%
17. Endothelial Progenitor Cells 25%
18. Reactive Oxygen Species 25%
19. Population 24%
20. Therapeutics 24%
21. Hypertension 23%
22. Angiotensin II 22%
23. Heart 21%
24. Antioxidants 21%
25. Cardiovascular Diseases 20%
26. Action Potentials 20%
27. Fibroblasts 19%
28. Coronary Artery Disease 19%
29. Nicorandil 19%
30. Rabbits 18%
31. Oxidative Stress 18%
32. Smooth Muscle Myocytes 18%
33. Inflammation 18%
34. Proteins 17%
35. Hydroxymethylglutaryl-CoA Reductase Inhibitors 17%
36. Homeostasis 17%
37. Electrocardiography 16%
38. Vaccination 16%
39. Human Influenza 16%
40. Mortality 16%
41. Stroke 16%
42. Kidney 15%
43. Chronic Renal Insufficiency 15%
44. Phosphorylation 15%
45. Hypertrophy 15%
46. Blood Vessels 15%
47. Apoptosis 15%
48. Histone Deacetylases 15%
49. Confidence Intervals 15%
50. Muscle Cells 15%
51. Peroxisome Proliferator-Activated Receptors 14%
52. Pravastatin 14%
53. Atherosclerosis 14%
54. Elderly 14%
55. Electrophysiology 14%
56. Down-Regulation 14%
57. Sinoatrial Node 14%
58. Gene Expression 14%
59. Superoxide Dismutase 14%
60. stevioside 13%
61. Human Umbilical Vein Endothelial Cells 13%
62. Diabetes Mellitus 13%
63. Nitric Oxide 13%
64. Neoplasms 13%
65. Atrial Remodeling 13%
66. Inbred SHR Rats 13%
67. KATP Channels 12%
68. Infarction 12%
69. Heme Oxygenase-1 12%
70. Ventricular Remodeling 12%
71. Extracellular Signal-Regulated MAP Kinases 12%
72. Incidence 12%
73. Type 2 Diabetes Mellitus 12%
74. Hospitalization 12%
75. Pharmaceutical Preparations 12%
76. urotensin II 11%
77. Fibrosis 11%
78. Lipids 11%
79. Glyburide 11%
80. Chronic Obstructive Pulmonary Disease 11%
81. Western Blotting 11%
82. Sitagliptin Phosphate 11%
83. Ventricular Tachycardia 11%
84. Lithium 11%
85. In Vitro Techniques 10%
86. p38 Mitogen-Activated Protein Kinases 10%
87. Glucose 10%
88. tanshinone 10%
89. Collagen 10%
90. Computed Tomography Angiography 10%
91. Cardiology 10%
92. C-Reactive Protein 10%
93. Antihypertensive Agents 10%
94. LCZ 696 10%
95. Nitric Oxide Synthase Type III 10%
96. Exercise 10%
97. Messenger RNA 10%
98. oxidized low density lipoprotein 10%
99. Thrombomodulin 10%
100. Dipeptidyl-Peptidase IV Inhibitors 10%